Frequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population

Axelsson, Uno; Bachmann, R.; Hällén, Jan

doi:10.1111/j.0954-6820.1966.tb05453.x

Cited by 398 publications

(71 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 immune StatuS An increased incidence of MGUS is documented in immunosuppressed and/or immunocompromised patients. An association between MGUS and human immunodeficiency virus (HIV)-seropositive (immunocompromised) patients has been reported, but this association has not been well Anagnostopoulos et al 15 Axelsson et al 16 Cohen et al 18 Iwanaga et al 19 Kyle et al 13 Prevalence ( Cohen et al 18 Landgren et al 22 Landgren et al 21 prevalence of MGUS For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings a .…”

Section: Sexmentioning

confidence: 99%

“…The studies reviewed demonstrate unequivocally that the prevalence of MGUS consistently increases with age. 13,[16][17][18][19]22 The median age of diagnosis is 70 years, and less than 2% of patients with MGUS are younger than 40 years. 13 Six of the investigations included in this review provided age-stratified breakdowns of prevalence (Figure 1).…”

Section: Sexmentioning

confidence: 99%

“…Three investigations were conducted independently in Sweden, 16 New Zealand, 17 and the United States 13 in primarily white populations. Only the study in the United States used modern electrophoretic methods.…”

Section: Sexmentioning

confidence: 99%

“…13,15,16,18,20,21,39,49 Differences in age composition of cohorts between studies influence sex-specific prevalence estimates because the condition is very rare in those younger than 40 years. For example, the population-based study by Axelsson et al 16 reported a prevalence of 1.1% in men and 0.8% in women aged 25 to 99 years. In contrast, investigations that only included older patients (>50 years) reported much higher prevalence estimates in men and women.…”

Section: Sexmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review

Wadhera

Rajkumar

2010

Mayo Clinic Proceedings

138

104

View full text Add to dashboard Cite

M onoclonal gammopathy of undetermined significance (MGUS) is a premalignant, asymptomatic disorder characterized by monoclonal plasma cell proliferation in bone marrow with absence of end-organ damage. 1 Although historically considered a benign condition, patients with MGUS have a lifelong risk of multiple myeloma, an incurable plasma cell malignancy with a median survival of approximately 4 to 5 years. [2][3][4] Patients with MGUS are also at risk of related disorders, such as light-chain amyloidosis and macroglobulinemia. Conditions such as osteoporosis, hip fractures, and peripheral neuropathy are also associated with MGUS. 5 The rate at which MGUS progresses to multiple myeloma or a related disorder is 1% per year. 6,7 The probability of progression at 25 years of follow-up is approximately 30%. However, after accounting for competing causes of death, true life-time probability of progression is lower (11%). 8 The risk of progression with MGUS does not diminish over time Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder that is associated with a lifelong risk of multiple myeloma. We conducted a systematic review of all studies investigating the prevalence and incidence of MGUS in the online database PubMed. The review was conducted from January 6, 2009, through January 15, 2010. The following MeSH search headings were used: monoclonal gammopathy, benign and prevalence; monoclonal gammopathy, benign and incidence; paraproteinemia and prevalence; and paraproteinemia and incidence. Articles were limited to those written in English and published by January 2009. Fourteen studies that met prespecified criteria were included and systematically assessed to identify the most accurate prevalence estimates of MGUS based on age, sex, and race. On the basis of our systematic review, we estimate that the crude prevalence of MGUS in those older than 50 years is 3.2% in a predominantly white population. Studies in white and Japanese populations demonstrate a clear increase in prevalence with age. The prevalence is also affected by sex: 3.7% and 2.9% in white men and women, respectively; and 2.8% and 1.6% in Japanese men and women, respectively. Additionally, MGUS is significantly more prevalent in black people (5.9%-8.4%) than in white people (3.0%-3.6%). We conclude that MGUS is a common premalignant plasma cell disorder in the general population of those older than 50 years. The prevalence increases with age and is affected by race, sex, family history, immunosuppression, and pesticide exposure. These results are important for counseling, clinical care, and the design of clinical studies in high-risk populations. and persists even in patients whose condition has remained stable for decades. 7,9 This fixed risk of progression regardless of duration of disease suggests a random 2-hit model of progression rather than a cumulative damage accumulation model in which the risk of progression would be expected to increase with duration of MGUS. The main risk factors for progressio...

show abstract

Section: Sexmentioning

confidence: 99%

Section: Sexmentioning

confidence: 99%

Section: Sexmentioning

confidence: 99%

Section: Sexmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review

Wadhera

Rajkumar

2010

Mayo Clinic Proceedings

138

104

View full text Add to dashboard Cite

show abstract

“…At the time of diagnosis of symptomatic MM up to a third of patients have a pre-existing diagnosis of one or more of these disorders, highlighting their asymptomatic nature (Kyle et al, 2003). MGUS, often considered a precursor state of MM affects nearly 3% of individuals over 70 years of age and has a low annual rate of progression to myeloma (<1%) (Axelsson et al, 1966;Kyle et al, 1972Kyle et al, , 2002Cesana et al, 2002;Rosinol et al, 2007). While increasing numbers of these patients are being identified as a result of the widespread use of protein electrophoresis, the majority of these patients will never evolve into myeloma or a related condition.…”

mentioning

confidence: 99%

Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders

et al. 2008

View full text Add to dashboard Cite

SummaryA third of patients with multiple myeloma (MM) have a preceding diagnosis of plasma cell proliferative disorder (PCPD), mostly monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM) or plasmacytoma. While autologous stem cell transplantation (SCT) improves survival in MM, it is not clear if patients with preceding PCPD have a different outcome. We identified 151 patients with preceding PCPD from among 804 patients undergoing SCT, and their outcomes were compared. The response rates, including complete responses, were similar between the groups. Patients with a preceding diagnosis of MGUS had longer time to progression (TTP; 27AE5 months vs. 17AE2 months, P = 0AE01), and longer overall survival (OS) from transplant (80AE2 months vs. 48AE3 months, P = 0AE03) compared to those with de novo myeloma. However no differences were seen among those with a preceding diagnosis of SMM or plasmacytoma in terms of TTP or OS from transplant when compared to those with de novo myeloma. Multivariate analysis indicated that the presence of MGUS prior to myeloma was prognostic for post-transplant relapse independent of other known risk factors. Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma.

show abstract

Monoclonal gammopathy in Sezary syndrome. Report of three cases and review of the literature

Venencie¹

1984

Archives of Dermatology

View full text Add to dashboard Cite

show abstract

Frequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population

Cited by 398 publications

References 18 publications

Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review

Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review

Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders

Monoclonal gammopathy in Sezary syndrome. Report of three cases and review of the literature

Contact Info

Product

Resources

About